Literature DB >> 20816582

Genome-wide association studies of cancer predisposition.

Zsofia K Stadler1, Joseph Vijai, Peter Thom, Tomas Kirchhoff, Nichole A L Hansen, Noah D Kauff, Mark Robson, Kenneth Offit.   

Abstract

Genome-wide association studies (GWAS) have now been performed in nearly all common malignancies and have identified more than 100 common genetic risk variants that confer a modest increased risk of cancer. For most discovered germline risk variants, the per allele effect size is small (<1.5) and the biologic mechanism of the detected association remains unexplained. Exceptions are the risk variants identified in JAK2 in myeloproliferative neoplasm and in the KITLG gene in testicular cancer, which are each associated with nearly a 3-fold increased risk of disease. GWAS have provided an efficient approach to identifying common, low-penetrance risk variants, and have implicated several novel cancer susceptibility loci. However, the identified low-penetrance risk variants explain only a small fraction of the heritability of cancer and the clinical usefulness of using these variants for cancer-risk prediction is to date limited. Studies involving more heterogeneous populations, determination of the causal variants, and functional studies are now necessary to further elucidate the potential biologic and clinical significance of the observed associations. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20816582     DOI: 10.1016/j.hoc.2010.06.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  18 in total

1.  Physicians' current practices and opportunities for DNA banking of dying patients with cancer.

Authors:  John M Quillin; Joann N Bodurtha; Laura A Siminoff; Thomas J Smith
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

2.  Detecting and exploiting etiologic heterogeneity in epidemiologic studies.

Authors:  Colin B Begg; Emily C Zabor
Journal:  Am J Epidemiol       Date:  2012-08-24       Impact factor: 4.897

3.  Cancer genomics and inherited risk.

Authors:  Zsofia K Stadler; Kasmintan A Schrader; Joseph Vijai; Mark E Robson; Kenneth Offit
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

Review 4.  Genomic Biomarkers for Breast Cancer Risk.

Authors:  Michael F Walsh; Katherine L Nathanson; Fergus J Couch; Kenneth Offit
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

5.  Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients.

Authors:  Scott M Langevin; E Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Heather H Nelson; Margaret R Karagas; Carmen J Marsit; John K Wiencke; Karl T Kelsey
Journal:  Epigenetics       Date:  2014-03-26       Impact factor: 4.528

6.  Two decades after BRCA: setting paradigms in personalized cancer care and prevention.

Authors:  Fergus J Couch; Katherine L Nathanson; Kenneth Offit
Journal:  Science       Date:  2014-03-28       Impact factor: 47.728

Review 7.  Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century.

Authors:  Muin J Khoury; Steven B Clauser; Andrew N Freedman; Elizabeth M Gillanders; Russ E Glasgow; William M P Klein; Sheri D Schully
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-27       Impact factor: 4.254

Review 8.  Comparative oncology: what dogs and other species can teach us about humans with cancer.

Authors:  Joshua D Schiffman; Matthew Breen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

Review 9.  The fate is not always written in the genes: epigenomics in epidemiologic studies.

Authors:  Scott M Langevin; Karl T Kelsey
Journal:  Environ Mol Mutagen       Date:  2013-02-26       Impact factor: 3.216

10.  Genome-wide association studies and epigenome-wide association studies go together in cancer control.

Authors:  Mukesh Verma
Journal:  Future Oncol       Date:  2016-04-15       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.